Stay updated on Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Sign up to get notified when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.

Latest updates to the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page
- Check5 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.9%
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check27 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check55 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check70 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about the treatment of myelofibrosis with fostamatinib, which included specific criteria for inclusion and exclusion in a clinical study. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference25%
- Check77 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.